Source:http://linkedlifedata.com/resource/pubmed/id/19763643
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
12
|
pubmed:dateCreated |
2010-1-21
|
pubmed:abstractText |
This study was performed to assess oral valganciclovir V-GCV (GCV pro-drug), 15 mg/kg bid for 6 weeks to 13 neonates with symptomatic congenital cytomegalovirus (CMV). We monitored plasma levels of GCV within 30 days of therapy: C(trough), and C(2h) (before and the 2 hours after administration), we performed viral assessment in plasma and urine and tolerability at baseline, and every fortnight. Pharmacokinetics showed GCV stable and effective plasma concentrations: mean C(trough) = 0.51 +/- 0.3 and C(2h) : 3.81 +/- 1.37 microg/ml. No significant variability was seen neither intra-patient nor inter-patients. One newborn discontinued therapy because of thrombocytopenia, another finished with a neutrophils count of 1,000/microl. At the end of therapy 6 out of 12 and 8 out of 12 newborns were negative for CMV in urine and plasma. The 4 newborns positive for CMV DNA showed a 90% reduction of pre-therapy values. Clinically, the 4 patients reporting hepatic disease and the 3 with thrombocytopenia recovered after 6 weeks of therapy. Eight newborns suffered from SNHL; at the 6-month follow-up no patients had worsened, 2 had improved, and no deterioration was reported in 3 newborns with chorioretinitis scarring. The paucity of adverse events, and the effectiveness and stability of drug plasma concentrations are the important findings of our study.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Dec
|
pubmed:issn |
1435-4373
|
pubmed:author | |
pubmed:issnType |
Electronic
|
pubmed:volume |
28
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1465-70
|
pubmed:meshHeading |
pubmed-meshheading:19763643-Administration, Oral,
pubmed-meshheading:19763643-Antiviral Agents,
pubmed-meshheading:19763643-Cytomegalovirus,
pubmed-meshheading:19763643-Cytomegalovirus Infections,
pubmed-meshheading:19763643-Drug Monitoring,
pubmed-meshheading:19763643-Female,
pubmed-meshheading:19763643-Ganciclovir,
pubmed-meshheading:19763643-Humans,
pubmed-meshheading:19763643-Infant, Newborn,
pubmed-meshheading:19763643-Infant, Newborn, Diseases,
pubmed-meshheading:19763643-Male,
pubmed-meshheading:19763643-Plasma,
pubmed-meshheading:19763643-Treatment Outcome,
pubmed-meshheading:19763643-Urine
|
pubmed:year |
2009
|
pubmed:articleTitle |
Oral valganciclovir treatment in newborns with symptomatic congenital cytomegalovirus infection.
|
pubmed:affiliation |
Neonatology and Neonatal Intensive Care Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
|
pubmed:publicationType |
Journal Article
|